Effects of Xuebijing injection combined with Budesonide in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease
Objective:To observe effects of Xuebijing injection combined with Budesonide in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:A prospective study was conducted on 82 patients with AECOPD admitted to the hospital from January 2022 to June 2023.According to the random number table method,they were divided into control group and study group,41 cases in each group.The control group was treated with Budesonide,while the study group was treated with Xuebijing injection on the basis of that of the control group.The clinical efficacy,the severity of the disease[modified medical research council(mMRC),COPD assessment test(CAT),6-minute walking test(6MWD)],the lung function indexes[maximum mid-expiratory flow rate(MMEF),forced vital capacity(FVC),maximum ventilation volume(MVV),forced expiratory volume in one second(FEV1)/FVC]levels,the inflammatory factors[procalcitonin(PCT),chemokine ligand 27(CCL27),tumor necrosis factor-α(TNF-α)]levels,the T cell subsets(CD3+,CD4+,CD4+/CD8+)levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 80.24%(37/41),which was higher than 73.17%(30/41)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the CAT and mMRC scores of the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;the 6MWD of the two groups were longer than those before the treatment,and that the study group was longer than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of MMEF,FVC,MVV and FEV1/FVC in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of PCT,CCL27 and TNF-α in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of CD3+,CD4+and CD4+/CD8+in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Xuebijing injection combined with Budesonide in the treatment of the AECOPD patients can improve the total effective rate,the lung function index levels and the T cell subgroup index levels,improve the disease severity index levels,and reduce the levels of inflammatory factors.Moreover,it is superior to simple Budesonide treatment.
万方数据
维普
